LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the completion of the sale of 1,050,000 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters of its previously announced public offering. After underwriting discounts and commissions and estimated offering expenses payable by Synta, aggregate net proceeds from the offering were approximately $32.9 million.
